These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 27721905)

  • 41. Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis.
    Lechtenboehmer CA; Burkard T; Reichenbach S; Walker UA; Burden AM; Hügle T
    Arthritis Res Ther; 2021 Oct; 23(1):267. PubMed ID: 34702319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of treatment of rheumatoid arthritis on periodontal disease: A review.
    Petit C; Culshaw S; Weiger R; Huck O; Sahrmann P
    Mol Oral Microbiol; 2024 Aug; 39(4):199-224. PubMed ID: 38363058
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hernández-Cruz B; Márquez-Saavedra E; Caliz-Caliz R; Navarro-Sarabia F
    Arthritis Res Ther; 2016 Nov; 18(1):259. PubMed ID: 27821150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Should We Use bDMARDs as an Induction Therapy in Early and Severe Rheumatoid Arthritis? Results at 5 years from the ERA UCLouvain Brussels Cohort.
    Sapart E; Sokolova T; de Montjoye S; Dierckx S; Nzeusseu A; Avramovska A; Meric de Bellefon L; Durez P
    Rheumatol Ther; 2023 Aug; 10(4):875-886. PubMed ID: 37183237
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis.
    Nakayama Y; Nagata W; Takeuchi Y; Fukui S; Fujita Y; Hosokawa Y; Ueno M; Ono K; Sumitomo S; Tabuchi Y; Nakanishi Y; Saito S; Ikeuchi H; Kawamori K; Sofue H; Doi G; Minami R; Hirota T; Minegishi K; Maeshima K; Motoyama R; Nakamura S; Suzuki S; Nishioka N; Wada TT; Onishi A; Nishimura K; Watanabe R; Yanai R; Kida T; Nishiwaki H; Yajima N; Kaneko Y; Tanaka E; Kawahito Y; Harigai M
    Mod Rheumatol; 2024 May; ():. PubMed ID: 38814660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis.
    Patel D; Shelbaya A; Cheung R; Aggarwal J; Park SH; Coindreau J
    Adv Ther; 2019 Aug; 36(8):2086-2095. PubMed ID: 31148057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
    Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
    Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.
    Bird P; Littlejohn G; Butcher B; Smith T; O'Sullivan C; Witcombe D; Griffiths H
    Clin Rheumatol; 2022 Jan; 41(1):53-62. PubMed ID: 34370130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between the prevalence of subclinical tenosynovitis and treatment in patients with RA in clinical remission: STARTER study.
    Parisi S; Zanetti A; Carrara G; Scirè CA; Iagnocco A; Filippou G;
    Rheumatology (Oxford); 2023 Apr; 62(4):1485-1492. PubMed ID: 36066434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol.
    Mueller RB; Spaeth M; von Restorff C; Ackermann C; Schulze-Koops H; von Kempis J
    J Clin Med; 2019 Mar; 8(3):. PubMed ID: 30832414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
    Simpson EL; Ren S; Hock ES; Stevens JW; Binard A; Pers YM; Archer R; Paisley S; Stevenson MD; Herpin C; Ghabri S
    Int J Technol Assess Health Care; 2019 Jan; 35(1):36-44. PubMed ID: 30722803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs.
    Keskin Y; Nas K; Kiliç E; Sargin B; Acer Kasman S; Alkan H; Şahin N; Cengiz G; Cuzdan N; Albayrak Gezer İ; Keskin D; Mülkoğlu C; Resorlu H; Ataman Ş; Bal A; Duruoz MT; Küçükakkas O; Yurdakul OV; Alkan Melikoğlu M; Aydin Y; Ayhan FF; Bodur H; Çaliş M; Çapkin E; Devrimsel G; Gök K; Hizmetli S; Kamanli A; Ecesoy H; Kutluk Ö; Şen N; Şendur ÖF; Tekeoğlu İ; Tolu S; Toprak M; Tuncer T
    Arch Rheumatol; 2021 Mar; 36(1):1-9. PubMed ID: 34046563
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
    Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
    Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy.
    Taylor PC; Balsa Criado A; Mongey AB; Avouac J; Marotte H; Mueller RB
    J Clin Med; 2019 Apr; 8(4):. PubMed ID: 30991730
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
    Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan.
    Chen DY; Yu F; Tuan LW; Tang CH
    Front Pharmacol; 2019; 10():1214. PubMed ID: 31695611
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.